title: Adenovirus type 12 E1B 55-kilodalton oncoprotein promotes p53-mediated apoptotic response of ovarian cancer to cisplatin.
abstract: The tumor suppressor p53-mediated apoptotic response plays an important role in cisplatin resistant in ovarian cancer. The adenovirus (Ad) type 12 E1B 55-kDa protein binds to p53 and inactivates its transcriptional transactivation function. In this study, we test the hypothesis that Ad12 E1B 55-kDa oncoprotein promotes p53-mediated apoptotic response of ovarian cancer to cisplatin. First, we observed the upregulation protein level of p53 target genes in cisplatin-resistant or cisplatin-sensitive ovarian cancer by Western blotting. Second, after transfection of Ad12 E1b 55-kDa expression plasmid, the expressions of p53 target genes in A2780 cells were further enhanced. Co-IP experiment demonstrated Ad12 E1b 55 kDa associated with p53. MTT assay confirmed that the cell proliferation was enhanced after transfection, as well as the enhanced cell inhibitory rate in the presence of cisplatin. Using flow cytometry, transfection of Ad12 E1B 55-kDa protein induced apoptosis and promoted S-phase transition in proliferation. Finally, results showed that all these changes promoted by Ad12 E1b 55 kDa were attenuated by the exposure of specific inhibitor of p53 signaling, pifithrin-α. Taken together, we concluded that Ad E1B 55-kDa oncoprotein promotes p53-mediated apoptotic response of ovarian cancer to cisplatin.
authors.affiliation: Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, The People's Republic of China.
authors.forename: Junnai
authors.initials: J
authors.lastname: Wang
authors.forename: Qinglei
authors.initials: Q
authors.lastname: Gao
authors.forename: Qiang
authors.initials: Q
authors.lastname: Li
mesh_terms: D000260:Adenoviruses, Human / Q000235:genetics; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects / Q000235:genetics; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005822:Genetic Vectors; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D014162:Transfection; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism; D014764:Viral Proteins / Q000235:genetics* / Q000378:metabolism
chemical_list: C553319:E1B55K protein, adenovirus; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D014764:Viral Proteins; D002945:Cisplatin
references.citation: Eur J Pharm Sci. 2015 Jan 23;66:138-47
references.pmid: 25312347
references.citation: Cancer Res. 2003 Nov 1;63(21):7081-8
references.pmid: 14612499
references.citation: Biochim Biophys Acta. 1996 Jun 7;1287(2-3):77-102
references.pmid: 8672531
references.citation: Mol Cell Biol. 2000 Aug;20(15):5540-53
references.pmid: 10891493
references.citation: Cell. 1982 Feb;28(2):387-94
references.pmid: 6277513
references.citation: Virology. 1990 Dec;179(2):806-14
references.pmid: 2146804
references.citation: Genes Dev. 1994 Jan;8(2):190-202
references.pmid: 8299938
references.citation: BMC Cancer. 2011 Sep 21;11:399
references.pmid: 21933447
references.citation: Virology. 1990 Dec;179(2):795-805
references.pmid: 2146803
references.citation: Chem Biodivers. 2010 Mar;7(3):543-66
references.pmid: 20232326
references.citation: Cancer Lett. 2013 Dec 1;341(2):231-9
references.pmid: 23962558
references.citation: Drug Resist Updat. 2011 Feb;14(1):22-34
references.pmid: 21251871
references.citation: Int J Gynaecol Obstet. 2001 Jan;72(1):55-60
references.pmid: 11146078
references.citation: Biochem Pharmacol. 2013 Apr 15;85(8):1077-90
references.pmid: 23396090
references.citation: Adv Exp Med Biol. 2008;622:197-208
references.pmid: 18546629
references.citation: Nature. 1992 May 7;357(6373):82-5
references.pmid: 1533443
references.citation: J Virol. 2003 Nov;77(21):11809-21
references.pmid: 14557665
references.citation: Virology. 1995 Oct 1;212(2):543-54
references.pmid: 7571424
references.citation: Nat Med. 1995 Oct;1(10):1052-6
references.pmid: 7489362
references.citation: Drug Resist Updat. 2002 Jul-Aug;5(3-4):131-46
references.pmid: 12237081
references.citation: Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S30-4
references.pmid: 19955911
references.citation: Virology. 1999 Feb 1;254(1):11-23
references.pmid: 9927570
references.citation: J Virol. 2003 Dec;77(24):13171-81
references.pmid: 14645574
references.citation: Nat Rev Clin Oncol. 2010 Apr;7(4):191-3
references.pmid: 20354543
references.citation: J Cell Biochem. 2007 Dec 1;102(5):1117-29
references.pmid: 17879946
references.citation: Oncogene. 2007 May 3;26(20):2860-72
references.pmid: 17072341
references.citation: Cell. 1993 Nov 19;75(4):805-16
references.pmid: 8242751
references.citation: Oncogene. 2012 Apr 12;31(15):1869-83
references.pmid: 21892204